Guardant Health, Inc. products

The Guardant Reveal™ test is the first blood-only liquid biopsy test that detects residual and recurrent disease in 7 days from a simple blood draw. The test detects any circulating tumor DNA (ctDNA) in blood after surgery to identify patients with residual disease who may benefit most from adjuvant therapy, and detects recurrence months earlier than current standard-of-care methods like carcinoembryonic antigen (CEA) tests or imaging. The commercially available test achieves industry-leading sensitivity (91%)7 for correctly detecting ctDNA and enables biopharma companies and academic researchers to identify new drug development opportunities to serve patients. The first indication of the test is early-stage CRC with additional cancer types to follow.